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Purpose: Cancer-associated retinopathy is a paraneoplastic retinal degeneration which may primarily result from 
auto-immune mediated apoptosis. It has been hypothesized that high titer of auto-antibodies are able to cross the 
blood-retinal barrier (BRB) and to enter retinal cells to activate apoptotic pathway which has been already 
well-established. However, it still remains to be elucidated whether auto-antibodies could cross BRB in the retina. 
Herein, we demonstrated that intravenously administrated anti-recoverin antibodies could not pass through BRB 
and not lead to retinal cell death.
Methods: Anti-recoverin antibody was intravenously injected to C57BL/6 mice, which were sacrificed 1 and 7 days 
to obtain eye. Vascular endothelial growth factor was intravitreally injected to induce BRB breakdown, which was 
confirmed by fluorescein angiography and western blotting for zonula occludens (ZO)-1, ZO-2 and occludin. To 
investigate the location of anti-recoverin antibody in the retina, immunofluorescein was performed. The retinal 
toxicity of intravenous anti-recoverin antibody was evaluated by histological examination and transferase-mediated 
dUTP nick-end labeling. Immunofluorescein staining for glial fibrillary acidic protein was done to address glial ac-
tivation as well. 
Results: Intravenously administrated anti-recoverin antibodies were exclusively distributed on retinal vessels which 
were co-localized with CD31, and led to neither increase of glial fibrillary acidic protein expression, as an indicator 
of retinal stress, nor apoptotic retinal cell death. Moreover, even in the condition of vascular endothelial growth 
factor-induced BRB breakdown, anti-recoverin antibodies could not migrate across BRB and still remained on 
retinal vessels without retinal cytotoxicity. 
Conclusions: Our results suggest that high titer of intravascular anti-recoverin antibodies could not penetrate into 
the retina by themselves, and BRB breakdown mediated by dysregulation of tight junction might not be sufficient 
to allow anti-recoverin antibodies to pass through BRB.
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Cancer-associated retinopathy (CAR) is a paraneoplastic 
neuronal degeneration in the retina of a cancer patient and is 
characterized by the rapid, progressive loss of vision [1]. The 
CAR has been described to occur with small-cell lung cancer, 
breast cancer, gynecological cancers, and others, in which the 
remote effects of cancers may stem from autoimmune responses 
of serum autoantibodies against both tumor and retinal pro-
teins [2,3]. Pathologically, CAR is the degeneration of photo-
receptors, with relative sparing of the inner retina, including 
ganglion cells, bipolar cells, amacrine cells, and horizontal 
cells, which are supplied by retinal vessels [1-3]. Although 
the precise mechanism has not been fully established, CAR Korean J Ophthalmol Vol.25, No.3, 2011
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may primarily result from autoimmune-mediated apoptosis, 
which is supported by the lack of inflammatory response to 
the retinal degeneration of CAR [4,5]. Among those auto-
antibodies found in sera of patients with CAR, those against 
the 23-kDa retinal protein recoverin appear to be the most 
common [1,6]. 
Recoverin is a cytoplasmic calcium-binding protein that is 
distributed in photoreceptor cells, bipolar cells, and in a small 
population of cells in the ganglion cell layer [7]. In CAR, it 
has been hypothesized that a high titer of autoantibodies are 
able to cross the blood-retinal barrier (BRB) and penetrate 
susceptible retinal cells, which is followed by cross-reactivity with 
particular retinal proteins [1,2]. Binding of the anti-recoverin 
antibody to recoverin enhances rhodopsin phosphorylation, 
continuously opens cGMP-gated channels, and increases the 
intracellular calcium level, which leads to activation of the 
caspase-dependent apoptotic pathway [5]. It has been al-
ready well-established that autoantibodies can enter and kill 
retinal cells [4,5], whereas it has never been established 
whether autoantibodies can cross the BRB [8,9]. In addition, 
although intravitreally injected autoantibodies successfully 
induced retinal degeneration and dysfunction similar to those 
of CAR [10,11], the intravitreal autoantibody injection is 
somehow different from the natural pathogenesis of CAR, in 
which it is hypothesized that circulating autoantibodies that 
cross the BRB enter retinal cells to induce cell death.
To maintain a stable environment in order to ensure the 
appropriate activities of retinal neurons, retinal vessels that 
supply the inner retina form the specialized structure of the 
BRB [11], which is regulated by modulating both angio-
genesis and tight junction formation, as described in our pre-
vious findings [12,13]. The BRB is actually located in retinal 
endothelial cells, whose specific junction molecules are 
requisite for the maintenance of the barrier function [13,14]. 
In retinal endothelial cells, tight junction proteins such as zon-
ula occludens (ZO)-1 and occludin are well-characterized, 
the expressions of which are inversely related to permeability 
in the BRB [13,15,16]. In a variety of retinal pathologies in-
cluding uveoretinitis, diabetic retinopathy, or age-related 
macular degeneration, diverse mechanisms might affect the 
integrity of the BRB and lead to breakdown [13,14]. Although 
less is understood about increased vascular permeability 
and extravasation from the bloodstream in BRB break-
down, it has been proposed that either process may occur to 
allow for migration through intercellular endothelial tight 
junctions and for trans-cellular migration through endothe-
lial cells [17,18].
In this study, we demonstrated that intravenously adminis-
trated anti-recoverin antibodies could not pass through the 
BRB and, therefore, do not cause retinal cell death. Moreover, 
even under the condition of BRB breakdown, anti-recoverin 
antibodies could not cross the BRB and remained on retinal 
vessels without retinal cytotoxicity.
Materials and Methods
Animals
Female C57BL/6 mice (eight- to ten-weeks-old, body weight 
22 ± 1.6 g) were purchased from Samtako (Seoul, Korea). 
Care, use, and treatment of all animals in this study were in 
strict compliance with the ARVO Statement for the Use of 
Animals in Ophthalmic and Vision Research. The mice were 
housed under standard 12-hour dark-light cycles at approx-
imately 23°C room temperature. After intravenous admin-
istration of anti-recoverin antibodies, the mice were sacrificed 
and enucleated at one and seven days. Each group contained ten 
animals. The enucleated eyes were immersion-fixed in 4% 
paraformaldehyde and subsequently embedded in paraffin.
Antibody
Anti-recoverin polyclonal antibodies (Chemicon International 
Inc., Temecula, CA, USA) were used in this study and were 
formulated in rabbit serum. According to the manufacturer’s 
specifications, the antibody has specificity for recoverin with 
immunogenicity for recombinant human recoverin and re-
acts with mouse recoverin, as well as those of primates, in-
cluding humans. Anti-recoverin antibodies (40 µL, 1 mg/mL) 
were intravenously administrated after dialysis to achieve 
systemic applications.
Cell culture
Human retinal microvascular endothelial
 cells (HRMECs) 
were purchased from the Applied Cell Biology
 Research 
Institute (Kirkland, WA, USA) and grown on attachment fac-
tor-coated plates
  in complete medium (Cell Systems, 
Kirkland, WA, USA). The HRMECs used in this study were 
taken from passages four to six.
Immunohistochemistry
Four-micron-thick serial sections were prepared from par-
affin blocks. Sections were deparaffinized and hydrated via 
sequential immersion in xylene and graded alcohol solutions, 
treated with proteinase K for 5 minutes at 37°C, and then 
treated with normal serum obtained from the same species in 
which the secondary antibody was developed for 10 minutes 
to block nonspecific staining. To stain intravenously admin-
istrated anti-recoverin antibodies, slides were incubated with 
FITC-conjugated IgG (1:400; Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) and TRITC-conjugated IgG (1:400; 
Jackson ImmunoResearch, Philadelphia, PA, USA). To stain 
endothelial cells or astrocytes, slides were incubated over-
night at 4°C with rabbit polyclonal antibody against CD31 
for endothelial cells (1:100, Santa-Cruz Biotechnology) or 
glial fibrillary acidic protein (GFAP) for astrocytes (1:100; 
Dako, San Francisco, CA, USA). FITC-conjugated IgG JH Kim, et al. No Anti-recoverin Antibody Crosses BRB
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Fig. 1. Intravenously administrated anti-recoverin antibodies could not pass through the blood-retinal barrier. After 
intravenous administration of anti-recoverin antibodies (1 mg/mL, 400 µL), the mice were sacrificed and enucleated 
before and one and seven days after injection. (A) Immunofluorescence staining for anti-recoverin antibody and 4’, 
6-diamidino-2-phenolindole (DAPI) staining for nuclei were performed. (B) Immunofluorescence staining of anti- 
recoverin antibody and CD31 as an endothelial cell marker and DAPI staining for nuclei were performed. Arrow in-
dicates merged immunofluorescence of anti-recoverin antibody and CD31. Asterisk indicates CD31-positive im-
munoreactivity without anti-recoverin antibody. Quantitative analysis for CD31- and anti-recoverin antibody-positive 
spots relative to all anti-recoverin antibody-positive spots was performed by measuring ten randomly-selected fields on 
each slide at 400×. Each point represents the mean (SD) of six independent experiments, *p < 0.05. Scale bar, 100 
μm. GCL = ganglion cell layer; IPL=inner plexiform layer; INL = inner nuclear layer; OPL=outer plexiform layer; 
ONL = outer nuclear layer; HPF=high power field.
(1:400, Santa Cruz Biotechnology) and TRITC-conjugated 
IgG (1:400, Jackson ImmunoResearch) were used as secon-
dary antibodies. For staining of nuclei, slides were stained 
with 10 μg/mL 4’, 6-diamidino-2-phenolindole (Sigma-Aldrich 
Co., St. Louis, MO, USA). The slides were observed under a 
fluorescence microscope (BX50; Olympus, Tokyo, Japan).
Terminal deoxynucleotidyl transferase-mediated dUTP 
nick-end labeling  assay
Four-micron-thick serial sections were prepared from 
paraffin blocks. Transferase-mediated dUTP nick-end label-
ing (TUNEL) staining was performed with a kit (ApopTag; 
Intergen, Purchase, NY, USA), according to the manu-
facturer’s instructions. TUNEL-positive cells were eval-
uated by two masked and independent observers (KJH and 
KJH) who viewed ten randomly-selected fields in each slide 
at a 400× magnification using a fluorescence microscope 
(BX50, Olympus).
Leakage assessment through the perfusion of retinal 
vessels with fluorescein-conjugated dextran
According to our recent study [16], one day following in-
travitreal injection of 20 ng/ml vascular endothelial growth 
factor (VEGF, Sigma-Aldrich Co.), deeply anesthetized mice 
were perfused through the tail vein with high molecular 
weight (MW = 500,000) fluorescein-conjugated dextran 
(Sigma-Aldrich Co.). At 1 hour post-perfuson, the eyes were 
enucleated and fixed in 4% paraformaldehyde for 2 hours. 
The retinas were dissected, flat-mounted in Dako mounting 
medium (DakoCytomation, Glostrup, Denmark), and viewed 
under fluorescence microscopy (BX50, Olympus) at 400×. 
These experiments were repeated at least three times.
Western blotting analysis
Western blotting was performed using standard Western 
blotting methods. The protein concentration was measured 
using a BCA protein assay kit (Pierce, Rockford, IL, USA). 
A
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Fig. 2. Intravenously administrated anti-recoverin antibodies never induced cytotoxicity in the retina. After intravenous ad-
ministration of anti-recoverin antibodies (1 mg/mL, 400 µL), the mice were sacrificed and enucleated before and one and 
seven days after injection. (A) The apoptotic cells in the sagittal sections from 12 to 6 o/c through the cornea parallel to the 
optic nerve were assessed using a transferase-mediated dUTP nick-end labeling (TUNEL) assay. TUNEL-positive cells 
were measured in ten randomly-selected fields on each slide at 400x. Each point represents the mean (SD) of six independent 
experiments, **p > 0.05. (B) Immunofluorescence staining of glial fibrillary acidic protein (GFAP), an astrocyte marker, 
was performed. Scale bar, 100 μm. DAPI = 4’, 6-diamidino-2-phenolindole; GCL = ganglion cell layer; INL = inner nu-
clear layer; ONL = outer nuclear layer; HPF=high power field.
Equal amounts of protein were separated via electrophoresis 
on a 5% to 10% SDS-PAGE gel and transferred electro-
phoretically onto a nitrocellulose membrane (Amersham, 
Little Chalfont, UK). The membranes were blocked for 30 
minutes in 5% non-fat milk. Next, the membranes were in-
cubated overnight with anti-CD31 (Santa Cruz Biotechnology), 
anti-ZO-1 (1:1000; Zymed, San Francisco, CA, USA), an-
ti-ZO-2 (1:2000, Zymed), and anti-occludin (1:1000, Zymed) 
at 4°C. After they were washed with phosphate balanced sol-
ution (PBS-T), the membrane was incubated for 1 hour at 
room temperature with horseradish peroxidase-conjugated 
anti-rabbit IgG or anti-mouse IgG (1:10,000; Pierce) in 
PBS-T and 1% non-fat milk. To ensure the equal loading of 
protein in each lane, the blots were stripped and reprobed 
with an antibody against ß-actin. Intensity values were nor-
malized relative to control values. The blots were scanned 
using a flatbed scanner, and the band intensity was analyzed 
using the TINA software program (Raytest, Straubenhardt, 
Germany).
Statistical analysis
Statistical differences between groups were evaluated with 
the Student unpaired t-test (two-tailed). Mean ± SD is shown. 
A p-value of less than 0.05 was considered significant.
Results
Intravenously administrated anti-recoverin antibodies 
could not pass through the BRB
To investigate whether intravenously administrated an-
ti-recoverin antibodies could cross the BRB, we injected 40 
µg of anti-recoverin antibodies into the tail veins of C57BL/6 
mice. As shown in Fig. 1A, anti-recoverin antibodies were 
exclusively detected in the inner retina, including the gan-
glion cell layer, inner plexiform layer, inner nuclear layer, 
and outer plexiform layer, whose distribution interestingly 
seemed to be confined to the retinal vessels. 
To address the distribution of anti-recoverin antibodies on 
retinal vessels, we compared the distribution of anti-recover-
in antibodies with the expression of CD31, an endothelial 
cell marker. Surprisingly, anti-recoverin antibodies were 
nearly co-localized with CD31 expression one day following 
injection, and the distribution pattern remained for seven 
days after injection, although much of the anti-recoverin an-
tibodies disappeared from the retina (Fig. 1B).
Intravenously administrated anti-recoverin antibodies 
never induced cytotoxicity in the retina
To examine whether intravenously administrated anti-re-
coverin antibodies could induce retinal cell death, based on 
A
BJH Kim, et al. No Anti-recoverin Antibody Crosses BRB
193
Fig. 3. Intravascular anti-recoverin antibodies could not pass through the blood-retinal barrier (BRB) in the case of BRB 
breakdown. (A) Fluorescein angiography using high molecular weight (500,000) fluorescein-conjugated dextran was performed to 
evaluate vascular endothelial growth factor (VEGF)-induced vascular leakage in the retina. One day following intravitreal injection 
of 20 ng/mL VEGF in 1 µL PBS or PBS only to mice, a whole mount retinal preparation was performed 1 hour post-perfusion with 
fluorescein-conjugated dextran. These experiments were repeated six times with similar results. Scale bar, 100 µm. (B) Human ret-
inal microvascular endothelial cells were incubated for 12 hours with 20 ng/mL VEGF. Western blot analysis for zonula occludens 
(ZO)-1, ZO-2, and occludin was performed. ß-Actin served as the loading control. Quantitative analysis was performed by measur-
ing protein expression relative to that of the control. Each point represents the mean (SD) of three independent experiments. *p < 
0.05. Figures were selected as representative data from three independent experiments. (C) Intravenous administration of anti-re-
coverin antibodies (1 mg/mL, 400 µL) was performed one day after intravitreal injection of 20 ng/mL VEGF. The mice were sacri-
ficed and enucleated one day after anti-recoverin antibody injection. Immunofluorescence staining of anti-recoverin antibody and 
CD31 as an endothelial cell marker and 4’, 6-diamidino-2-phenolindole (DAPI) staining for nuclei were performed. Arrow in-
dicates merged immunofluorescence of anti-recoverin antibody and CD31. Quantitative analysis for CD31- and anti-recoverin anti-
body-positive spots relative to all anti-recoverin antibody-positive spots was performed by measuring ten randomly-selected fields 
on each slide at 400x. Each point represents the mean (SD) of six independent experiments, *p < 0.05. Scale bar, 100 μm. GCL 
= ganglion cell layer; INL = inner nuclear layer; ONL = outer nuclear layer; HPF=high power field.
the previous reports of apoptotic cell death induced by auto-
antibodies, we evaluated apoptotic cell death in the retina using 
a TUNEL assay. As demonstrated in Fig. 2A, intravenously ad-
ministrated anti-recoverin antibodies never induced retinal 
apoptotic cell death, as would be expected if they could not 
cross the BRB. In addition, we investigated whether intravenously 
administrated anti-recoverin antibodies could up-regulate 
GFAP expression in the retina as an indicator of retinal stress 
[19]. The injection of anti-recoverin antibodies never induced 
a progressive increase in GFAP in Mueller cells (Fig. 2B).
Intravascular anti-recoverin antibodies could not pass 
through the BRB under breakdown conditions
To evaluate whether intravenously administrated anti-re-
coverin antibodies could pass through the BRB under the 
conditions of BRB breakdown, we induced VEGF-mediated 
BRB breakdown via intravitreal injection of 20 ng/mL 
VEGF and analyzed the passage of autoantibodies across the 
BRB. Intravitreal injection of VEGF disrupts the BRB and 
induces profuse leakage from retinal vessels (Fig. 3A), which 
is closely linked to a decrease in tight junction proteins in ret-
inal endothelial cells (Fig. 3B) [14,18]. Even during BRB 
breakdown, intravenously administrated anti-recoverin anti-
bodies were confined to retinal vessels without passage 
across the BRB, were co-localized with CD31, and were de-
tected on retinal vessels with a similar frequency to that of 
the control (Fig. 3C).
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Fig. 4. Intravenously administrated anti-recoverin antibodies under blood-retinal barrier breakdown conditions never increased retinal cell 
death. Intravenous administration of anti-recoverin antibodies (1 mg/mL, 400 µL) was performed one day after intravitreal injection of 20 
ng/mL vascular endothelial growth factor (VEGF). The mice were sacrificed and enucleated one and seven days after anti-recoverin antibody 
injection. The apoptotic cells in the sagittal sections from 12 to 6 o/c through the cornea parallel to the optic nerve were assessed using a trans-
ferase-mediated dUTP nick-end labeling (TUNEL) assay. TUNEL-positive cells were measured in ten randomly-selected fields on each slide 
at 400x. Each point represents the mean (SD) of six independent experiments, **p > 0.05. Scale bar, 100 μm. DAPI = 4’, 6-diamidino- 
2-phenolindole; GCL = ganglion cell layer; INL = inner nuclear layer; ONL = outer nuclear layer; HPF=high power field.  
Intravenously administrated anti-recoverin antibodies 
under BRB breakdown conditions never increased retinal 
cell death
To examine whether intravenously administrated anti-re-
coverin antibodies under BRB breakdown conditions could 
induce retinal apoptotic cell death, a TUNEL assay was 
performed. As demonstrated in Fig. 4, there was no sig-
nificant change in apoptotic cell count with or without BRB 
breakdown.
Discussion
CAR has been thought to be mediated by the autoimmune 
reactions triggered by antigenic mimicry, where anti-recov-
erin antibody plays a crucial role in the pathogenesis of CAR, 
resulting in retinal degeneration [2,4-6]. It is hypothesized 
that autoantibodies against recoverin develop from a tumor 
antigen resembling one shared by recoverin, and a high titer 
of circulating antibodies may increase the possibility of pas-
sage through the BRB. Although retinal degeneration in 
CAR may be mediated by both humoral and cellular immune 
mechanisms [20], it is not clear whether either plays a major 
role. As proposed in other autoimmune diseases, anti-recov-
erin antibodies are able to enter into retinal cells and induce 
apoptotic cell death, which has been demonstrated in retinal 
tissue in vivo as well as in an in vitro retinal cell culture 
[4,5,9,10]. However, we still do not know how anti-recoverin 
antibodies pass through the BRB because anti-recoverin anti-
bodies were intravitreally injected in the in vivo experiments. 
In this study, we demonstrated that intravenously adminis-
trated anti-recoverin antibodies could not pass through the 
BRB. Based on the high titer of autoantibodies in CAR pa-
tient serum samples [1,2], it has been hypothesized that a 
high titer of anti-recoverin antibodies is consequently related 
to penetration through the BRB. In addition, cancer patients 
with a low titer of anti-recoverin antibodies were reported to 
demonstrate no visual dysfunction [8]. Given that the blood 
volume in mice is about 85 to 95 mL/kg [21], and the body 
weight of the mice used in our experiment was 22 ± 1.6 g, the 
amount of intravenous injection, 40 µg, is a relatively high 
titer compared to the serum concentration of CAR patients 
[1,2]. However, anti-recoverin antibodies were exclusively 
observed in the retinal vessels. Interestingly, anti-recoverin 
antibodies still remained on retinal vessels for seven days after 
intravenous administration, although the frequency decreased. 
Furthermore, intravenous administration of anti-recoverin 
antibodies never induced any retinal stress, confirmed by a 
lack of change in GFAP expression, as well as no retinal cell 
death. It is reasonable to speculate that these results occurred 
as a result of no anti-recoverin antibodies crossing the BRB.
Based on retinal vascular changes indicating BRB break-
down in CAR [22], the pathogenesis of CAR might be linked 
to BRB breakdown. The BRB is a selective barrier that repre-
sents the boundary between the systemic circulation and the 
retinal neuron. Vascular permeability in the retina is there-
fore actively regulated by the BRB, which is established with 
a tight junction restricting the paracellular flux of molecules 
[12,13,18]. VEGF is causally linked to BRB breakdown 
through the dysregulation of the tight junction, which leads 
to increased retinal vascular permeability [13,18]. In addition, 
VEGF upregulates intracellular adhesion molecule
 (ICAM)-1 
in retinal endothelial cells, which increases leukocyte adhe-
sion [23]. 
The ICAM-1 in endothelial cells activates a Rho A-mediated 
signal to allow leukocytes to paracellularly migrate across JH Kim, et al. No Anti-recoverin Antibody Crosses BRB
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the barrier through the interendothelial cell junction or trans-
cellularly through the endothelial cell itself [17]. In this 
study, we induced BRB breakdown via intravitreal injection 
of VEGF, which might enhance penetration of intravascular 
anti-recoverin antibodies into the retina. Surprisingly, there 
was no passage of anti-recoverin antibody through the BRB 
in the case of VEGF-induced BRB breakdown. In addition, 
anti-recoverin antibodies were observed on retinal vessels 
with a similar frequency to that of the control, which in part 
supports the idea that penetration of anti-recoverin anti-
bodies through the BRB might not be mediated by regu-
lation of the tight junction in restriction of paracellular flux, 
although this is not certain for the transcellular route. The 
interpretation of this result is only speculative and requires 
further investigation.
In conclusion, intravenously administrated anti-recoverin 
antibodies could not pass through the BRB, which therefore 
does not induce either retinal stress or retinal cell death. 
Interestingly, intravascular anti-recoverin antibodies could 
not migrate into the retina even in VEGF-induced BRB 
breakdown, which also was not accompanied by an increase 
in retinal cell death. On the basis of the available evidence, 
we suggest that intravascular anti-recoverin antibodies could 
not naturally penetrate into the retina, and BRB breakdown 
mediated by dysregulation of the tight junction might not be 
sufficient to allow anti-recoverin antibodies to pass through 
the BRB. Further investigations are required to elucidate oth-
er transporting routes of intravascular anti-recoverin anti-
bodies to the retina and for the sustained existence of intra-
venous administrated anti-recoverin antibodies on retinal 
vessels.
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